Currently, there are 20.22M common shares owned by the public and among those 17.42M shares have been available to trade.
The company’s stock has a 5-day price change of 59.46% and 68.57% over the past three months. RGLS shares are trading 84.37% year to date (YTD), with the 12-month market performance up to 87.30% higher. It has a 12-month low price of $0.76 and touched a high of $2.14 over the same period. RGLS has an average intraday trading volume of 39.42K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 58.50%, 72.29%, and 70.40% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Regulus Therapeutics Inc (NASDAQ: RGLS) shares accounts for 45.34% of the company’s 20.22M shares outstanding.
It has a market capitalization of $47.72M and a beta (3y monthly) value of 1.45. The earnings-per-share (ttm) stands at -$1.59. Price movements for the stock have been influenced by the stock’s volatility, which stands at 24.62% over the week and 11.12% over the month.
Analysts forecast that Regulus Therapeutics Inc (RGLS) will achieve an EPS of -$0.4 for the current quarter, -$0.39 for the next quarter and -$1.59 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.42 while analysts give the company a high EPS estimate of -$0.39. Comparatively, EPS for the current quarter was -$0.4 a year ago. Earnings per share for the fiscal year are expected to increase by 14.34%, and 33.05% over the next financial year. EPS should shrink at an annualized rate of 39.60% over the next five years, compared to 56.20% over the past 5-year period.
Looking at the support for the RGLS, a number of firms have released research notes about the stock. B. Riley FBR Inc. stated their Neutral rating for the stock in a research note on March 28, 2018, with the firm’s price target at $1. Leerink Partners coverage for the Regulus Therapeutics Inc (RGLS) stock in a research note released on January 05, 2018 offered a Outperform rating with a price target of $2. Chardan Capital Markets was of a view on June 13, 2017 that the stock is Buy, while Wedbush gave the stock Outperform rating on March 06, 2017, issuing a price target of $8- $6. Wells Fargo on their part issued Market Perform rating on January 30, 2017.
